TherapeuticsMD, Inc. operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen. The company also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaMedMD and BocaGreenMD brands. It markets its products primarily through a direct national sales force to health care providers in the OB/GYN market space. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone561-961-1900
Debt
Current Ratio7.23
Quick Ratio7.15
Price-To-Earnings
Sales & Book Value
Annual Sales$16.78 million
Price / Sales73.43
Price / Cash FlowN/A
Price / Book8.63
Profitability
Net Income$-76,920,000.00
Net Margins-757.59%
Return on Assets-67.96%
Miscellaneous
Employees173
OptionableOptionable
TherapeuticsMD (NASDAQ:TXMD) Frequently Asked Questions
What is TherapeuticsMD's stock symbol?
TherapeuticsMD trades on the NASDAQ under the ticker symbol "TXMD."
How were TherapeuticsMD's earnings last quarter?
TherapeuticsMD Inc (NASDAQ:TXMD) announced its quarterly earnings results on Wednesday, November, 7th. The company reported ($0.16) EPS for the quarter, beating the Zacks' consensus estimate of ($0.22) by $0.06. The business had revenue of $3.47 million for the quarter, compared to analyst estimates of $4.43 million. TherapeuticsMD had a negative net margin of 757.59% and a negative return on equity of 102.15%. TherapeuticsMD's quarterly revenue was down 21.5% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.07) EPS. View TherapeuticsMD's Earnings History.
When is TherapeuticsMD's next earnings date?
What price target have analysts set for TXMD?
4 brokers have issued 12 month target prices for TherapeuticsMD's shares. Their forecasts range from $11.00 to $27.00. On average, they anticipate TherapeuticsMD's share price to reach $17.3333 in the next twelve months. This suggests a possible upside of 234.6% from the stock's current price. View Analyst Price Targets for TherapeuticsMD.
What is the consensus analysts' recommendation for TherapeuticsMD?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TherapeuticsMD in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for TherapeuticsMD.
Has TherapeuticsMD been receiving favorable news coverage?
News stories about TXMD stock have been trending somewhat negative on Wednesday, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. TherapeuticsMD earned a news sentiment score of -1.2 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 5.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the company's share price in the near term.
Are investors shorting TherapeuticsMD?
TherapeuticsMD saw a increase in short interest in December. As of December 31st, there was short interest totalling 70,149,536 shares, an increase of 0.9% from the December 14th total of 70,801,039 shares. Based on an average daily trading volume, of 4,302,831 shares, the days-to-cover ratio is presently 16.3 days. Approximately 35.9% of the company's stock are short sold. View TherapeuticsMD's Current Options Chain.
Who are some of TherapeuticsMD's key competitors?
Some companies that are related to TherapeuticsMD include TESARO (TSRO), FibroGen (FGEN), Amneal Pharmaceuticals (AMRX), GW Pharmaceuticals PLC- (GWPH), Horizon Pharma (HZNP), Array Biopharma (ARRY), Taro Pharmaceutical Industries (TARO), Intercept Pharmaceuticals (ICPT), Emergent Biosolutions (EBS), Evotec (EVTCY), Agios Pharmaceuticals (AGIO), Ascendis Pharma A/S (ASND), Blueprint Medicines (BPMC), HUTCHISON CHINA/S (HCM) and Akcea Therapeutics (AKCA).
Who are TherapeuticsMD's key executives?
TherapeuticsMD's management team includes the folowing people:
- Mr. Robert G. Finizio, Co-Founder, CEO & Director (Age 47)
- Mr. John C. K. Milligan IV, Pres, Sec. & Director (Age 56)
- Dr. Brian A. Bernick, Co-Founder, Chief Clinical Officer & Director (Age 50)
- Mr. Daniel Alan Cartwright, CFO & Treasurer (Age 60)
- Mr. Mitchell L. Krassan, Exec. VP & Chief Strategy Officer (Age 52)
Who are TherapeuticsMD's major shareholders?
TherapeuticsMD's stock is owned by a number of of institutional and retail investors. Top institutional investors include Sanders Morris Harris LLC (0.18%). Company insiders that own TherapeuticsMD stock include Brian Bernick, Daniel A Cartwright, John CK Iv Milligan, Robert G Finizio and Tommy G Thompson. View Institutional Ownership Trends for TherapeuticsMD.
Which major investors are buying TherapeuticsMD stock?
How do I buy shares of TherapeuticsMD?
Shares of TXMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is TherapeuticsMD's stock price today?
One share of TXMD stock can currently be purchased for approximately $5.18.
How big of a company is TherapeuticsMD?
TherapeuticsMD has a market capitalization of $1.20 billion and generates $16.78 million in revenue each year. The company earns $-76,920,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. TherapeuticsMD employs 173 workers across the globe.
What is TherapeuticsMD's official website?
How can I contact TherapeuticsMD?
TherapeuticsMD's mailing address is 6800 BROKEN SOUND PARKWAY NW, BOCA RATON FL, 33487. The company can be reached via phone at 561-961-1900 or via email at [email protected]
MarketBeat Community Rating for TherapeuticsMD (NASDAQ TXMD)
MarketBeat's community ratings are surveys of what our community members think about TherapeuticsMD and other stocks. Vote "Outperform" if you believe TXMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TXMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
